Quest Diagnostics (DGX) Gets FDA Clearance for Simplexa C. difficile Test on (MMM)

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M (NYSE: MMM) Integrated Cycler.

The test, from the company's Focus Diagnostics business, is intended to aid in the diagnosis of Clostridium difficile-associated disease, one of the most common and dangerous acquired infections in healthcare settings. It uses a proprietary technique to eliminate the time consuming nucleic-acid sample extraction process required by many other molecular tests, for potentially faster results reporting for hospitals and clinical laboratories.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Quest Diagnostics (DGX) PT Raised to $145 at Evercore ISI
• Alvotech (ALVO) Reports Topline Results from a Confirmatory Clinical Study for AVT05
• Rocket Lab USA (RKLB) Successfully Deploys Satellites ~500km Apart to Separate Orbits For KAIST and NASA